Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.40 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.40 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.40 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.40 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.40 |
| ▸ | CDK1 | P06493 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | ARG1 | P05089 | 1/20 | 0.32 |
| ▸ | ARG2 | P78540 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5025557 | 0.98 | CYP1A2 (0.45) | CYP1A2CYP2C9MAPK1HPGDHIF1A | |
| SCHEMBL3317331 | 0.88 | CYP1A2 (0.45) | CYP1A2CYP2C9MAPK1HPGDHIF1A | |
| SCHEMBL5028381 | 0.87 | PRMT3 (0.46) | CYP1A2CYP2C9MAPK1HPGDHIF1A | |
| SCHEMBL8305883 | 0.87 | PRMT3 (0.46) | CYP1A2CYP2C9MAPK1HPGDHIF1A | |
| SCHEMBL4808961 | 0.87 | PRMT3 (0.50) | CYP1A2CYP2C9MAPK1HPGDHIF1A | |
| SCHEMBL10282626 | 0.86 | PAOX (0.38) | CYP1A2CYP2C9MAPK1HPGDHIF1A | |
| Hydrochloric Acid SCHEMBL5024036 | 0.85 | PRMT3 (0.43) | CYP1A2CYP2C9MAPK1HPGDHIF1A | |
| SCHEMBL10244307 | 0.85 | CYP1A2 (0.42) | CYP1A2CYP2C9MAPK1HPGDHIF1A | |
| SCHEMBL15120484 | 0.84 | PRMT3 (0.39) | CYP1A2CYP2C9MAPK1HPGDHIF1A | |
| Diethylaminoethanol SCHEMBL9291291 | 0.84 | CYP1A2 (0.41) | CYP1A2CYP2C9MAPK1HPGDHIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4328309-A2 | LIPID COMPOSITION | FUJIFILM Corporation (JP) | 2024-02-28 | — | — | EP | disclosed |
| WO-2017120536-A1 | POLYETHYLENIMINE (PEI)-POLYPEPTIDE CONJUGATES AND METHODS OF USE THEREOF | APG THERAPEUTICS, INC. (US) | 2017-07-13 | — | — | WO | disclosed |
| US-20170114062-A1 | BENZAMIDE OR BENZAMINE COMPOUNDS USEFUL AS ANTICANCER AGENTS FOR THE TREATMENT OF HUMAN CANCERS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2017-04-27 | — | — | US | disclosed |
| US-8097708-B2 | 10a-Azalide compound | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-01-17 | — | — | US | disclosed |
| US-20100104659-A1 | BENZOPYRANOPYRAZOLES | 4SC AG (DE) | 2010-04-29 | — | — | US | disclosed |
| US-20090281292-A1 | 10a-Azalide Compound | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2009-11-12 | — | — | US | disclosed |
| US-7442791-B2 | Aminoalkylamide substituted cyclohexyl derivatives | HOFFMANN-LA ROCHE INC. (US) | 2008-10-28 | — | — | US | disclosed |
| EP-1667962-A1 | AMINOALKYLAMIDE SUBSTITUTED CYCLOHEXYL DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2006-06-14 | — | — | EP | disclosed |
| WO-2005097768-A2 | NOVEL GAMMA SECRETASE INHIBITORS | SCHERING CORPORATION (US) | 2005-10-20 | — | — | WO | disclosed |
| WO-2005028427-A1 | AMINOALKYLAMIDE SUBSTITUTED CYCLOHEXYL DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2005-03-31 | — | — | WO | disclosed |
| US-20050065210-A1 | Aminoalkylamide substituted cyclohexyl derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2005-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050065210-A1 | Aminoalkylamide substituted cyclohexyl derivatives | LSS, CYP51A1, CYP46A1 | CYP1A2 135/4885CYP2C9 412/4885MAPK1 2015/4885 |
| US-20170114062-A1 | BENZAMIDE OR BENZAMINE COMPOUNDS USEFUL AS ANTICANCER AGENTS FOR THE TREATMENT OF HUMAN CANCERS | ACAT1, ACAT2, NPC1L1 | CYP1A2 1284/4885CYP2C9 2458/4885MAPK1 1801/4885 |
| US-20090281292-A1 | 10a-Azalide Compound | IL17A, AZI2, HDAC9 | CYP1A2 1928/4885CYP2C9 395/4885MAPK1 2104/4885 |
| US-20100104659-A1 | BENZOPYRANOPYRAZOLES | BAX, BCL2, BAD | CYP1A2 647/4885CYP2C9 2263/4885MAPK1 1096/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.